全文获取类型
收费全文 | 40275篇 |
免费 | 2979篇 |
国内免费 | 1533篇 |
专业分类
耳鼻咽喉 | 253篇 |
儿科学 | 888篇 |
妇产科学 | 627篇 |
基础医学 | 4475篇 |
口腔科学 | 913篇 |
临床医学 | 4418篇 |
内科学 | 5892篇 |
皮肤病学 | 1529篇 |
神经病学 | 1507篇 |
特种医学 | 886篇 |
外国民族医学 | 8篇 |
外科学 | 2202篇 |
综合类 | 6069篇 |
现状与发展 | 5篇 |
一般理论 | 1篇 |
预防医学 | 2562篇 |
眼科学 | 545篇 |
药学 | 8553篇 |
73篇 | |
中国医学 | 1356篇 |
肿瘤学 | 2025篇 |
出版年
2024年 | 48篇 |
2023年 | 768篇 |
2022年 | 994篇 |
2021年 | 1622篇 |
2020年 | 1647篇 |
2019年 | 1390篇 |
2018年 | 1257篇 |
2017年 | 1217篇 |
2016年 | 1151篇 |
2015年 | 1225篇 |
2014年 | 2315篇 |
2013年 | 2359篇 |
2012年 | 2184篇 |
2011年 | 2480篇 |
2010年 | 2154篇 |
2009年 | 1857篇 |
2008年 | 1919篇 |
2007年 | 2071篇 |
2006年 | 1737篇 |
2005年 | 1786篇 |
2004年 | 1439篇 |
2003年 | 1395篇 |
2002年 | 1168篇 |
2001年 | 1070篇 |
2000年 | 954篇 |
1999年 | 878篇 |
1998年 | 781篇 |
1997年 | 690篇 |
1996年 | 557篇 |
1995年 | 630篇 |
1994年 | 550篇 |
1993年 | 407篇 |
1992年 | 380篇 |
1991年 | 293篇 |
1990年 | 198篇 |
1989年 | 143篇 |
1988年 | 133篇 |
1987年 | 129篇 |
1986年 | 103篇 |
1985年 | 106篇 |
1984年 | 108篇 |
1983年 | 90篇 |
1982年 | 85篇 |
1981年 | 74篇 |
1980年 | 52篇 |
1979年 | 41篇 |
1978年 | 25篇 |
1977年 | 43篇 |
1976年 | 37篇 |
1973年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 468 毫秒
61.
Wen Chen Yun Zhao Xing Xie Jihong Liu Jingran Li Chao Zhao Shaoming Wang Xueyan Liao Qiong Shou Minghuan Zheng Alfred J Saah Lihui Wei Youlin Qiao 《Vaccine》2019,37(6):889-897
Background
A quadrivalent human papillomavirus (qHPV) vaccine (HPV6/11/16/18) has demonstrated efficacy and acceptable safety in international studies. However, these studies did not include participants from mainland China, which has a substantial burden of HPV-related disease. This is the first safety report with a follow-up period of up to 90?months from a randomized, double-blind, placebo-controlled trial of qHPV vaccine in Chinese women 20–45?years of age.Methods
Participants were randomized 1:1 to receive three doses of qHPV vaccine or placebo (Day 1, Month 2, and Month 6). Efficacy outcomes are reported elsewhere. Injection-site and systemic adverse events (AEs) were collected using vaccination report cards (VRCs) for 15?days following each vaccination. Serious AEs (SAEs), pregnancy outcomes, new medical conditions, and fetal/infant SAEs were collected during the entire study.Results
Of 3006 participants randomized, AEs were reported by 926 (61.8%) qHPV vaccine recipients and 856 (57.1%) placebo recipients over the entire study. Four participants (two in each group) discontinued the study vaccination due to AEs that were considered vaccination-related. Within 15?days following any vaccination, injection-site AEs prompted for on the VRC were more frequent among qHPV vaccine recipients (37.6% vs 27.8%), and systemic AEs prompted for on the VRC were similar in frequency between qHPV vaccine and placebo groups (46.8% vs 45.1%). Thirty-eight and 43 participants reported SAEs in qHPV vaccine and placebo groups, respectively. No SAE was considered qHPV vaccine-related. Pregnancy outcomes, fetal/infant SAEs, and new medical conditions were generally similar in frequency between the qHPV vaccine and placebo groups, and within normal ranges.Conclusion
The qHPV vaccine was well tolerated and demonstrated a favorable safety profile in Chinese women 20–45?years of age, consistent with findings from global trials and safety surveillance studies.Trial registration: clinicaltrials.gov; NCT00834106. 相似文献62.
63.
Wei-Fan Hsu Po-Heng Chuang Cheng-Kuo Chen Hung-Wei Wang Ming-Hung Tsai Wen-Pang Su Hung-Yao Chen Chi-Ying Yang Chun-Che Lin Guan-Tarn Huang Jaw-Town Lin Hsueh-Chou Lai Cheng-Yuan Peng 《American journal of cancer research》2020,10(12):4547
Real-world predictors of the treatment efficacy of immune checkpoint inhibitors for hepatocellular carcinoma (HCC) are unknown. This retrospective study enrolled 87 consecutive patients with unresectable HCC from May 2017 to December 2019 at two hospitals. Of the 87 patients, 7, 9, 60, and 11 patients had Barcelona Clinic Liver Cancer stages A, B, C, and D, respectively, and 45, 30, and 10 patients were Child-Pugh class A, B, and C, respectively. The median injection numbers of nivolumab and treatment duration were 6 (3-8) and 2.53 (1.47-4.23) months, respectively, and 64.4% of patients received combination therapy. Radiological imaging was not assessed for 25 patients. Objective response (OR) and disease control rates were 19.5% and 39.1%, respectively. A single tumor (odds ratio: 9.542, P = .015) and ≥20% decline in serum α-fetoprotein protein (AFP) levels within the first 3 months of treatment (defined as AFP response, odds ratio: 5.997, P = .042) were predictors of OR. Lack of macrovascular invasion, combination therapy, and AFP response were predictors of progression-free survival. A Cancer of the Liver Italian Program (CLIP) score of 0-2 (hazard ratio [HR]: 3.717, P = .004) and grade 1-2 immune-related adverse events (irAEs, HR: 2.217, P = .049) were predictors of overall survival (OS) in the entire cohort, and a CLIP score of 0-2 (HR: 3.257, P = .009) was a predictor of OS in evaluable patients. IrAEs ≥ grade 3 were noted in 14 patients, and three died as a result. Having a single tumor and AFP response were predictors of OR, and CLIP score was a predictor of OS. 相似文献
64.
BackgroundAlthough colitis has been reported in patients treated with immune checkpoint inhibitors (ICIs), associations between colitis and ICIs had not been thoroughly assessed in real-world studies. Here, we identified and characterized significant colitis-associated with ICIs.MethodsBased on the Food and Drug Administration Adverse Event Reporting System (FAERS) from January 2004 to December 2019, the disproportionality analysis and Bayesian analysis, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN) and the multi-item gamma Poisson shrinker (MGPS) algorithms were adopted to data mining of the suspected adverse events of colitis after ICIs administrating. Clinical characteristics of patients with ICIs-associated colitis and the time to onset of colitis following different ICI regimens were collected.ResultsA total of 3786 reports of colitis adverse events were identified with ICIs. Seven ICI monotherapies were associated with the reporting of colitis. Statistically significant ROR, PRR, information component (IC), and empirical Bayesian geometric mean (EBGM) emerged for all ICI monotherapies and combination therapies. ICIs-associated colitis affected mostly male (53.51%), with a wide mean age range (60.65 to 72 years). Colitis adverse events were commonly reported in patients with melanoma and lung cancer. Adverse outcomes of colitis concerning ICI were mainly outcomes of hospitalization-initiated or prolonged and other serious. Among colitis cases, 17.43% cases of colitis concerning ICI lead to death. The adverse event of colitis occurred earliest in ipilimumab monotherapy with a median time to onset of 64.21 days (IQR: 27–69 days) among all monotherapies.ConclusionsICI may lead to severe and disabling ICIs-associated colitis during therapy. Analysis of FAERS data identified signals for adverse events of colitis with ICI regimens. Practitioners should consider the factors that may increase the likelihood of colitis. The findings support a continued surveillance and risk factor identification studies. 相似文献
65.
《The ocular surface》2020,18(2):249-257
PurposeTo evaluate the safety and effectiveness of the intranasal tear neurostimulator (ITN) in improving dry eye symptoms assessed in a controlled adverse environment (CAE®).MethodsStudy 1: Multicenter, subject-masked, randomized-sequence, crossover design. Single intranasal (active) and extranasal (control) ITN administration during CAE exposure. Study 2: Single-arm, open-label design. Intranasal ITN administration ≥2 times/day for 45 days, CAE assessment at days 0 and 45. In both studies, upon CAE entry, and every 5 min thereafter, subjects assessed eye dryness score (visual analog scale, 0–100 mm; EDS-VAS), and ocular discomfort score (ODS; Ora Calibra™, 0–4), for ≈2 h. Study 1: when ODS was ≥3 at 2 consecutive timepoints, subjects applied ITN intranasally or extranasally for ≈3 min, and again when achieving the same ODS criteria in randomized sequence. Study 2: days 0 and 45, ITN was applied for ≈3 min employing the same ODS criteria as Study 1.ResultsStudy 1: Significantly greater pre- to post-application reductions in mean [SEM] EDS (−16.5 [1.7] vs −3.1 [1.7], P < 0.0001) and ODS (−0.93 [0.08] vs −0.34 [0.08], P < 0.0001; n = 143) with intranasal vs extranasal stimulation. Study 2: On day 0 (n = 52) and day 45 (n = 48), significant pre- to post-application reductions in mean [SEM] EDS (−15.9 [2.7] and −15.2 [2.4]; P < 0.0001), and ODS (−1.3 [0.2] and −1.3 [0.1]; P < 0.0001). Few device-related adverse events were reported, none serious.ConclusionsAcute symptom relief is significant with the ITN and remains undiminished after daily use. 相似文献
66.
67.
68.
69.
70.
Adverse pregnancy outcomes (APOs) have been defined as (a) pre-term birth, when there is a delivery before 37 completed weeks (<259 days); (b) pre-eclampsia, which is a multisystem disorder of pregnancy characterized by maternal hypertension and proteinuria after the 20th gestational week; (c) low and very low birthweight, depending on whether the weight of the baby is less of 2500 g or <1500 g and (d) the spontaneous death of the fetus with <20 weeks (miscarriage) or between 20 and 36 weeks (stillbirth). In 2012, during the Consensus Report from the Joint EFP/AAP workshop on periodontitis and systematic diseases the role of periodontal diseases on APOs was reviewed. Some years later, this evidence has grown, and an update on the literature regarding the mechanisms related to this potential association (APOs and periodontal diseases) needs to be presented. The two major pathways (direct and indirect) already accepted in 2012 are still valid nowadays. Most evidence published in the last 5 years deals with a strong and solid evidence coming from the direct pathway while there is as scarce new evidence regarding indirect pathway. In this direct pathway, the haematological dissemination of oral microorganisms and their products, would later induce an inflammatory/Immune response in the foetal-placental unit. The most plausible route for this direct pathway is the hematogenous transmission through dental bacteremia, although not many new studies dealing with bacteremia has been performed lately. 相似文献